AKT1 and acute lymphoblastic leukemia: These insights strengthen the potential of NSP‐B as a novel therapeutic agent in T‐ALL treatment, offering a multifaceted approach by targeting both the PI3K/AKT and mTOR pathways and influencing apoptotic regulators.